Skip to main content

Branded

  • Valeant buys Solta Medical

    LAVAL, Quebec — Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

    The Canadian drug maker said the $2.92-per-share acquisition represented a 40% premium over Solta's closing share price on Friday. Solta develops, manufactures and markets energy-based medical device systems for such cosmetic medical procedures as skin tightening, improving skin texture and others.

  • Walgreens collaborates with CDC on comprehensive HIV treatment model

    DEERFIELD, Ill. — In support of the more than 1.1 million people living with HIV in the United States, Walgreens on Monday announced its collaboration with the Centers for Disease Control and Prevention to develop and evaluate a model of HIV patient-centered care through a national project aimed at advancing clinical integration and medication therapy management. The program is another way Walgreens is extending its commitment to improve HIV prevention and treatment outcomes.

  • CDC: Flu vaccination prevented an estimated 6.6 million influenza-associated illnesses last season

    ATLANTA — Flu vaccination prevented an estimated 6.6 million influenza-associated illnesses, 3.2 million medically attended illnesses, and 79,000 hospitalizations during the 2012-2013 flu season, according to a Centers for Disease Control and Prevention report in the Morbidity and Mortality Weekly Report published Thursday. CDC also reported today that despite the benefits of flu vaccination, only 40% of Americans 6 months and older had reported getting a flu vaccine this season as of early November 2013.

  • Irish High Court approves Perrigo-Elan deal

    ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

  • Reports: ESI may start 'price war' over new hepatitis C drugs

    NEW YORK — Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

    Bloomberg News reported that ESI would pit companies like Gilead Sciences against others such as AbbVie when the new treatments become available in 2014 or 2015. The Food and Drug Administration announced last week the approval of Gilead's new drug, Sovaldi (sofosbuvir), which is designed to cut by three quarters the time needed for treatment.

  • Study: GSK’s FluLaval Quadrivalent reduces flu cases among children ages 3 years to 8 years by 55.4%

    PHILADELPHIA — GlaxoSmithKline on Wednesday announced that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK’s FluLaval Quadrivalent reduced flu cases among children ages 3 years to 8 years by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. 

  • FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy

    PRINCETON, N.J. — A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.

  • Novo Nordisk provides funding for diabetes initiatives

    NEW YORK — Diabetes organizations in several cities are getting a boost in funding from a Danish drug maker that specializes in developing treatments for the disease.

    Novo Nordisk said it would provide funding to groups in Seattle; Portland, Ore.; and Rochester, Minn., as part of the Novo Nordisk Community Care initiative. The initiative provides funding to nonprofits that support educational programs for people with Type 2 diabetes.

X
This ad will auto-close in 10 seconds